Peanut allergy could be a thing of the past for many sufferers, thanks to an innovative treatment in development by ProTA Therapeutics. Newly available capital provided through the Australian Government’s Biomedical Translation Fund (BTF) is stimulating investment in innovative health and medical discoveries. Three new investment funds supported through the BTF are investing in companies in their early stages who are, or will be, developing and commercialising biomedical discoveries. The fund will help strengthen the Australian biomedical industry and create the jobs of the future, benefiting both the economy and the Australian people. The first company to receive investment, ProTA Therapeutics, received a $10 million commitment from OneVentures Healthcare Fund III. ProTA’s treatment uses oral immunotherapy technology to allow those with peanut allergies to incorporate peanuts and peanut products into their regular diets—something that will be for both child and adult sufferers. The investment commitment delivered by OneVentures will help the company to advance the development of this promising new treatment for food allergies affecting both kids and adults. The funds will also be critical to advancement of the clinical program in Melbourne, Adelaide and Perth. Recruitment is expected to be completed by the fourth quarter of 2018, with the study providing evidence of a longer-lasting tolerance to peanuts and helping to compare the effects of probiotic peanut oral immunotherapy against peanut immunotherapy on its own. treatment is innovative, in that it’s the first to allow children with peanut allergies to be able to consume peanuts. In a clinical it was found to induce peanut tolerance in more than 80 per cent of children treated. While the treatment currently focuses on this type of allergy, it is expected that it may be applicable to other food allergies like milk, eggs and other nuts in the future, giving it enormous potential. It is thanks to the BTF that companies like ProTA are able to continue their important work to help improve the health of Australians and assist the industry to fulfil its full potential through innovation. For further information on the BTF, visit the
Peanut allergy could be a thing of the past for many sufferers, thanks to an innovative treatment in development by ProTA Therapeutics. Newly available capital provided through the Australian Government’s Biomedical Translation Fund (BTF) is stimulating investment in innovative health and medical discoveries. Three new investment funds supported through the BTF are investing in companies in their early stages who are, or will be, developing and commercialising biomedical discoveries. The fund will help strengthen the Australian biomedical industry and create the jobs of the future, benefiting both the economy and the Australian people. The first company to receive investment, ProTA Therapeutics, received a $10 million commitment from OneVentures Healthcare Fund III. ProTA’s treatment uses oral immunotherapy technology to allow those with peanut allergies to incorporate peanuts and peanut products into their regular diets—something that will be for both child and adult sufferers. The investment commitment delivered by OneVentures will help the company to advance the development of this promising new treatment for food allergies affecting both kids and adults. The funds will also be critical to advancement of the clinical program in Melbourne, Adelaide and Perth. Recruitment is expected to be completed by the fourth quarter of 2018, with the study providing evidence of a longer-lasting tolerance to peanuts and helping to compare the effects of probiotic peanut oral immunotherapy against peanut immunotherapy on its own. treatment is innovative, in that it’s the first to allow children with peanut allergies to be able to consume peanuts. In a clinical it was found to induce peanut tolerance in more than 80 per cent of children treated. While the treatment currently focuses on this type of allergy, it is expected that it may be applicable to other food allergies like milk, eggs and other nuts in the future, giving it enormous potential. It is thanks to the BTF that companies like ProTA are able to continue their important work to help improve the health of Australians and assist the industry to fulfil its full potential through innovation. For further information on the BTF, visit the
isa_annual_report_2016-17_accessible_version.docx